scholarly journals Using Pharmacokinetics to Optimize Antiretroviral Drug-Drug Interactions in the Treatment of Human Immunodeficiency Virus Infection

2000 ◽  
Vol 30 (Supplement_2) ◽  
pp. S123-S129 ◽  
Author(s):  
John G. Gerber
Keyword(s):  
Human Immunodeficiency Virus ◽  
Virus Infection ◽  
Human Immunodeficiency Virus Infection ◽  
Drug Interactions ◽  
Antiretroviral Drug ◽  
Immunodeficiency Virus

scholarly journals Clarithromycin lowers plasma zidovudine levels in persons with human immunodeficiency virus infection.

1997 ◽  
Vol 41 (8) ◽  
pp. 1709-1714 ◽  
Author(s):  
M A Polis ◽  
S C Piscitelli ◽  
S Vogel ◽  
F G Witebsky ◽  
P S Conville ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Virus Infection ◽  
Human Immunodeficiency Virus Infection ◽  
Drug Interactions ◽  
Maximum Concentration ◽  
Opportunistic Infections ◽  
Simultaneous Administration ◽  
Time Curve ◽  
Antiretroviral Agents ◽  
Immunodeficiency Virus

The use of antiretroviral agents and drugs for the treatment and prophylaxis of opportunistic infections has lengthened the survival of persons with AIDS. In the era of multidrug therapy, drug interactions are important considerations in designing effective and tolerable regimens. Clarithromycin has had a significant impact on the treatment of disseminated Mycobacterium avium complex infection, and zidovudine is the best-studied and one of the most widely used antiretroviral agents in this population. We conducted a study to determine the maximally tolerated dose of clarithromycin and the pharmacokinetics of clarithromycin and zidovudine individually and in combination. Mixing studies were conducted to simulate potential interaction in the gastric environment. The simultaneous administration of zidovudine and clarithromycin had little impact on the pharmacokinetics of clarithromycin or of its major metabolite. However, coadministration of zidovudine and clarithromycin at three doses (500 mg orally [p.o.] twice daily [b.i.d.], 1,000 mg p.o. b.i.d., and 2,000 mg p.o. b.i.d.) reduced the maximum concentration of zidovudine by 41% (P < 0.005) and the area under the concentration-time curve from 0 to 4 h for zidovudine by 25% (P < 0.05) and increased the time to maximum concentration of zidovudine by 84% (P < 0.05), compared with zidovudine administered alone. Mixing studies did not detect the formation of insoluble complexes due to chelation, suggesting that the decrease in zidovudine concentrations results from some other mechanism. Simultaneous administration of zidovudine and clarithromycin appears to decrease the levels of zidovudine in serum, and it may be advisable that these drugs not be given at the same time. Drug interactions should be carefully evaluated in persons with advanced human immunodeficiency virus infection who are receiving multiple pharmacologic agents.

PS-022 Polypharmacy and drug-drug interactions in adults with human immunodeficiency virus infection

2015 ◽  
Vol 22 (Suppl 1) ◽  
pp. A144.2-A145
Author(s):  
P Lopez-Sanchez ◽  
JM Martínez-Sesmero ◽  
AR Rubio Salvador ◽  
M García Palomo ◽  
P Moya-Gomez
Keyword(s):  
Human Immunodeficiency Virus ◽  
Virus Infection ◽  
Human Immunodeficiency Virus Infection ◽  
Drug Interactions ◽  
Immunodeficiency Virus

Relevance of the Organic Cation Transporters 1 and 2 for Antiretroviral Drug Therapy in Human Immunodeficiency Virus Infection

2008 ◽  
Vol 36 (8) ◽  
pp. 1616-1623 ◽  
Author(s):  
Norma Jung ◽  
Clara Lehmann ◽  
Andrea Rubbert ◽  
Meike Knispel ◽  
Pia Hartmann ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Drug Therapy ◽  
Virus Infection ◽  
Human Immunodeficiency Virus Infection ◽  
Organic Cation ◽  
Organic Cation Transporters ◽  
Antiretroviral Drug ◽  
Immunodeficiency Virus ◽  
Cation Transporters

Cutaneous non-epidermotropic lymphoma associated with human immunodeficiency virus infection

1997 ◽  
Vol 22 (6) ◽  
pp. 262-264 ◽  
Author(s):  
R. VIRABEN ◽  
P. BROUSSET ◽  
C. AQUILINA ◽  
L. LAMANT
Keyword(s):  
Human Immunodeficiency Virus ◽  
Virus Infection ◽  
Human Immunodeficiency Virus Infection ◽  
Immunodeficiency Virus

360 Immune-related asymptomatic cardiac involvement in human immunodeficiency virus infection: An echocardiographic study

1999 ◽  
Vol 1 ◽  
pp. S63-S63
Author(s):  
F HERNANDEZ ◽  
P ESCRIBANO ◽  
M VELAZQUEZ ◽  
J COSTA ◽  
R DALMAU ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Virus Infection ◽  
Human Immunodeficiency Virus Infection ◽  
Cardiac Involvement ◽  
Echocardiographic Study ◽  
Immunodeficiency Virus

Rapid diameter expansion of aortic aneurysm after human immunodeficiency virus infection

VASA ◽  
2015 ◽  
Vol 44 (5) ◽  
pp. 387-390
Author(s):  
Thomas Kotsis ◽  
Louizos-Alexandros Louizos ◽  
Spyridon Mylonas ◽  
Evangelos Pappas ◽  
Karandrea Despoina ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Aortic Aneurysm ◽  
Virus Infection ◽  
Human Immunodeficiency Virus Infection ◽  
Immunodeficiency Virus

Rhodococcus pneumonia in human-immunodeficiency-virus infection

Pneumologie ◽  
2008 ◽  
Vol 62 (S 2) ◽  
Author(s):  
R Hörster ◽  
A Strassburg ◽  
J Welling ◽  
U Greinert ◽  
M Jafari ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Virus Infection ◽  
Human Immunodeficiency Virus Infection ◽  
Immunodeficiency Virus
Sign in / Sign up

Export Citation Format

Share Document